{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T20:36:21Z","timestamp":1785443781169,"version":"3.56.0"},"reference-count":48,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>After years of global collaboration; we are steps away from a polio-free world. However, the currently conventional inactivated polio vaccine (cIPV) is suboptimal for the post eradication era. cIPV production cost and biosafety hazards hinder its availability and coverage of the global demands. Production of IPV from the attenuated Sabin strains (sIPV) was an ideal solution and scientists work extensively to perfect a safe, effective and affordable sIPV. This study investigated the ability of hydrogen peroxide (H2O2), ascorbic acid (AA) and epigallocatechin-3-gallate (EGCG) as alternatives for Formaldehyde (HCHO) to inactivate Sabin-polioviruses strains for sIPV production. Sabin-polioviruses vaccine strains were individually treated with AA, EGCG or H2O2 and were compared to HCHO. This was investigated by determination of the inactivation kinetics on HEP2C cells, testing of D-antigen preservation by ELISA and the immune response in Wistar rats of the four vaccine preparations. H2O2, AA and EGCG were able to inactivate polioviruses within 24 h while HCHO required 96 h. Significant high D-antigen levels were observed using AA, EGCG and H2O2 compared to HCHO. Rat sera tested for neutralizing antibodies showed comparable results. These findings support the idea of using these inactivating agents as safe and time- saving alternatives for HCHO to produce sIPV.<\/jats:p>","DOI":"10.3390\/vaccines8040601","type":"journal-article","created":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T21:48:38Z","timestamp":1602625718000},"page":"601","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["In-Vitro Inactivation of Sabin-Polioviruses for Development of Safe and Effective Polio Vaccine"],"prefix":"10.3390","volume":"8","author":[{"given":"Asmaa A.","family":"Abd-Elghaffar","sequence":"first","affiliation":[{"name":"Biotechnology Unit, National Organization for Research and Control of Biological (NORCB), Giza 12654, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed E.","family":"Rashed","sequence":"additional","affiliation":[{"name":"Bacterial Control Unit, National Organization for Research and Control of Biological (NORCB), Giza 12654, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal E.","family":"Ali","sequence":"additional","affiliation":[{"name":"Microbiology and Immunology Department, Faculty of Pharmaceutical Sciences &amp; Pharmaceutical Industries, Future University in Egypt, New Cairo 12311, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdy A.","family":"Amin","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,13]]},"reference":[{"key":"ref_1","unstructured":"(2020, July 03). WHO|Oral Polio Vaccine (OPV). Available online: https:\/\/www.who.int\/biologicals\/areas\/vaccines\/polio\/opv\/en\/."},{"key":"ref_2","unstructured":"(2020, July 03). GPEI-Polio Endgame Strategy. Available online: http:\/\/polioeradication.org\/who-we-are\/polio-endgame-strategy-2019-2023\/."},{"key":"ref_3","unstructured":"WHO (2020, August 03). WHO|SAGE Meeting of April 2020. Available online: http:\/\/www.who.int\/immunization\/sage\/meetings\/2020\/april\/en\/."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Thompson, K.M., and Kalkowska, D.A. (2020). Potential Future Use, Costs, and Value of Poliovirus Vaccines. Risk Anal.","DOI":"10.1111\/risa.13557"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Tobin, G.J., Tobin, J.K., Gaidamakova, E.K., Wiggins, T.J., Bushnell, R.V., Lee, W.-M., Matrosova, V.Y., Dollery, S.J., Meeks, H.N., and Kouiavskaia, D. (2020). A novel gamma radiation-inactivated sabin-based polio vaccine. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0228006"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1016\/j.vaccine.2017.03.008","article-title":"Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: A novel dose sparing immunization schedule","volume":"35","author":"Anand","year":"2017","journal-title":"Vaccine"},{"key":"ref_7","unstructured":"(2020, August 03). WHO|Fractional Dose IPV. Available online: http:\/\/www.who.int\/immunization\/diseases\/poliomyelitis\/endgame_objective2\/inactivated_polio_vaccine\/fractional_dose\/en\/."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"(2020, August 03). 1,25-Dihydroxyvitamin D3 Enhances Systemic and Mucosal Immune Responses to Inactivated Poliovirus Vaccine in Mice|The Journal of Infectious Diseases|Oxford Academic. Available online: https:\/\/academic.oup.com\/jid\/article\/193\/4\/598\/827482.","DOI":"10.1086\/499970"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.vaccine.2012.12.076","article-title":"Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains","volume":"31","author":"Westdijk","year":"2013","journal-title":"Vaccine"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.vaccine.2016.12.027","article-title":"First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12months and 5years of age","volume":"35","author":"Lindgren","year":"2017","journal-title":"Vaccine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6979","DOI":"10.1016\/j.vaccine.2018.09.068","article-title":"An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6\u00ae cell culture platform is immunogenic and safe in a non-human primate model","volume":"36","author":"Bockstal","year":"2018","journal-title":"Vaccine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.biologicals.2016.08.005","article-title":"Development of inactivated poliovirus vaccine from Sabin strains: A progress report","volume":"44","author":"Okayasu","year":"2016","journal-title":"Biologicals"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/infdis\/jiy736","article-title":"Immunogenicity and Safety of a Sabin Strain\u2013Based Inactivated Polio Vaccine: A Phase 3 Clinical Trial","volume":"220","author":"Hu","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/cid\/cix110","article-title":"Immune Serum from Sabin Inactivated Poliovirus Vaccine Immunization Neutralizes Multiple Individual Wild and Vaccine-Derived Polioviruses","volume":"64","author":"Sun","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"11955","DOI":"10.1128\/JVI.01809-14","article-title":"Effect of Formaldehyde Inactivation on Poliovirus","volume":"88","author":"Wilton","year":"2014","journal-title":"J. Virol."},{"key":"ref_16","unstructured":"Rutala, W.A. (2008). Guideline for Disinfection and Sterilization in Healthcare Facilities, DCD."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.vaccine.2015.12.041","article-title":"Inactivation of rabies virus by hydrogen peroxide","volume":"34","author":"Ali","year":"2016","journal-title":"Vaccine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/nm.2763","article-title":"Development of a new hydrogen peroxide\u2013based vaccine platform","volume":"18","author":"Amanna","year":"2012","journal-title":"Nat. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/0264-410X(91)90289-I","article-title":"Safety and immunogenicity of hydrogen peroxide-inactivated pertussis toxoid in 18-month-old children","volume":"9","author":"Siber","year":"1991","journal-title":"Vaccine"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijid.2003.09.002","article-title":"In vitro inactivation of the rabies virus by ascorbic acid","volume":"8","author":"Madhusudana","year":"2004","journal-title":"Int. J. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Olayan, E., El-Khadragy, M., Mohamed, A.F., Mohamed, A.K., Shebl, R.I., and Yehia, H.M. (2020, June 16). Evaluation of Different Stabilizers and Inactivating Compounds for the Enhancement of Vero Cell Rabies Vaccine Stability and Immunogenicity: In Vitro Study. Available online: https:\/\/www.hindawi.com\/journals\/bmri\/2019\/4518163\/.","DOI":"10.1155\/2019\/4518163"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Lee, Y.H., Jang, Y.H., Byun, Y.H., Cheong, Y., Kim, P., Lee, Y.J., Lee, Y.J., Sung, J.M., Son, A., and Lee, H.M. (2017). Green Tea Catechin-Inactivated Viral Vaccine Platform. Front. Microbiol., 8.","DOI":"10.3389\/fmicb.2017.02469"},{"key":"ref_23","unstructured":"WHO (2020, March 22). WHO Expert Committee on Biological Standardization\u2014WHO Technical Report Series, No. 980\u2014Sixty-Third Report_Annex 2_Recommendations to Assure the Quality, Safety and Efficacy of Poliomyelitis Vaccines (Oral, Live, Attenuated). Available online: https:\/\/apps.who.int\/medicinedocs\/en\/m\/abstract\/Js21348en\/."},{"key":"ref_24","unstructured":"American Veterinary Medical Association (2007). AVMA Guidelines on Euthanasia 2007, AVMA."},{"key":"ref_25","unstructured":"Wilson, D.E., and Chosewood, L.C. (2009). Biosafety in Microbiological and Biomedical Laboratories, CDC. [5th ed.]."},{"key":"ref_26","unstructured":"WHO (1997). Manual of Laboratory Methods for Testing of Vaccines Used in the WHO Expanded Programme on Immunization."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1128\/JVI.02903-12","article-title":"A Hydrogen Peroxide-Inactivated Virus Vaccine Elicits Humoral and Cellular Immunity and Protects against Lethal West Nile Virus Infection in Aged Mice","volume":"87","author":"Pinto","year":"2013","journal-title":"J. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0092-1157(86)90028-4","article-title":"Inactivation of poliovirus with beta-propiolactone","volume":"14","author":"Jiang","year":"1986","journal-title":"J. Biol. Stand."},{"key":"ref_29","unstructured":"WHO (2002). WHO_TRS_910_Annex2. Recommendations for the Production and Control of Poliomyelitis Vaccine (inactivated), WHO Expert Committee on Biological Standardization: Fifty-First Report."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Crowther, J.R. (2009). The ELISA Guidebook: Second Edition. Methods in Molecular Biology, Humana Press. [2nd ed.].","DOI":"10.1007\/978-1-60327-254-4"},{"key":"ref_31","first-page":"114","article-title":"Evaluation of inactivation efficacy of Sabin Polio virus using different inactivating agents and its immunogenicity post nano and micro incapsulation","volume":"1","author":"Ali","year":"2010","journal-title":"Int. J. Microbiol. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/978-1-4939-3292-4_15","article-title":"Methods for the Quality Control of Inactivated Poliovirus Vaccines","volume":"Volume 1387","year":"2016","journal-title":"Poliovirus"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1590\/0074-02760160119","article-title":"Calculation of the ELISA\u2019s cut-off based on the change-point analysis method for detection of Trypanosoma cruzi infection in Bolivian dogs in the absence of controls","volume":"111","author":"Lardeux","year":"2016","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"ref_34","unstructured":"WHO (2020, April 29). Guidelines for WHO\/EPI Collaborative Studies on Poliomyelitis: Standard Procedure for Determining Immunity to Poliovirus Using the Microneutralization Test. Available online: https:\/\/apps.who.int\/iris\/handle\/10665\/70486."},{"key":"ref_35","first-page":"979","article-title":"Inactivation of poliovirus by formaldehyde","volume":"17","author":"Gard","year":"1957","journal-title":"Bull. World Health Organ."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"7041","DOI":"10.1016\/j.vaccine.2007.07.060","article-title":"Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains","volume":"25","author":"Tano","year":"2007","journal-title":"Vaccine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1016\/j.vaccine.2011.02.085","article-title":"Characterization and standardization of Sabin based inactivated polio vaccine: Proposal for a new antigen unit for inactivated polio vaccines","volume":"29","author":"Westdijk","year":"2011","journal-title":"Vaccine"},{"key":"ref_38","first-page":"544","article-title":"Differences in Antigenic Structure of Inactivated Polio Vaccines Made from Sabin Live-Attenuated and Wild-Type Poliovirus Strains: Impact on Vaccine Potency Assays","volume":"221","author":"Crawt","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.provac.2011.10.002","article-title":"Non-animal replacement methods for human vaccine potency testing: State of the science and future directions","volume":"5","author":"McFarland","year":"2011","journal-title":"Procedia Vaccinol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1016\/j.vaccine.2020.03.027","article-title":"Effects of the thermal denaturation of Sabin-derived inactivated polio vaccines on the D-antigenicity and the immunogenicity in rats","volume":"38","author":"Murakami","year":"2020","journal-title":"Vaccine"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1128\/cdli.4.6.659-664.1997","article-title":"Evaluation of a poliovirus-binding inhibition assay as an alternative to the virus neutralization test","volume":"4","author":"Herremans","year":"1997","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"ref_42","unstructured":"Plotkin, S.A., Orenstein, W.A., and Offit, P.A. (2012). Vaccines, Elsevier\/Saunders. [6th ed.]."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Gao, J. (2020). P-values\u2014A chronic conundrum. BMC Med. Res. Methodol., 20.","DOI":"10.1186\/s12874-020-01051-6"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/d41586-019-00857-9","article-title":"Scientists rise up against statistical significance","volume":"567","author":"Amrhein","year":"2019","journal-title":"Nature"},{"key":"ref_45","unstructured":"(2020, September 15). P-Values and Statistical Significance|Simply Psychology. Available online: https:\/\/www.simplypsychology.org\/p-value.html."},{"key":"ref_46","unstructured":"(2020, September 15). Strategy for the Response to Type 2 Circulating Vaccine-Derived Poliovirus 2020\u20132021. Available online: http:\/\/polioeradication.org\/wp-content\/uploads\/2020\/04\/Strategy-for-the-response-to-type-2-circulating-Vaccine-Derived-Poliovirus-20200406.pdf."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0140-6736(19)31279-6","article-title":"The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: A double-blind, single-centre phase 1 study","volume":"394","author":"Damme","year":"2019","journal-title":"Lancet"},{"key":"ref_48","unstructured":"(2020, September 15). Advancing Novel Polio Vaccines. Available online: https:\/\/path.azureedge.net\/media\/documents\/nOPV-Fact-Oct2020.pdf."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/4\/601\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:20:13Z","timestamp":1760178013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/4\/601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,13]]},"references-count":48,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["vaccines8040601"],"URL":"https:\/\/doi.org\/10.3390\/vaccines8040601","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,13]]}}}